Matrix metalloproteinases: Regulators of the tumor microenvironment, Cell, vol.141, pp.52-67, 2010. ,
Physiology and pathophysiology of matrix metalloproteases, Amino Acids, vol.41, pp.271-290, 2011. ,
A 25 kda alpha 2-microglobulin-related protein is a component of the 125 kda form of human gelatinase, FEBS Lett, vol.314, pp.386-388, 1992. ,
Isolation and primary structure of ngal, a novel protein associated with human neutrophil gelatinase, J. Biol. Chem, vol.268, pp.10425-10432, 1993. ,
Biological activity and clinical implications of the matrix metalloproteinases, Anticancer Res, vol.28, pp.1389-1397, 2008. ,
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer, J. Clin. Oncol, vol.27, pp.5287-5297, 2009. ,
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer, Biochim. Biophys. Acta, vol.1826, pp.129-169, 2012. ,
Neutrophil gelatinase-associated lipocalin in acute kidney injury, Adv. Clin. Chem, vol.58, pp.141-191, 2012. ,
Lipocalin 2: A multifaceted modulator of human cancer, Cell Cycle, vol.8, pp.2347-2352, 2009. ,
Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene, Cancer Lett, vol.288, pp.10-16, 2010. ,
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g., acute leukemia, Crit. Rev. Oncol. Hematol, vol.50, pp.87-100, 2004. ,
Matrix metalloproteinases in bone marrow: Roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies, Histol. Histopathol, vol.21, pp.519-531, 2006. ,
Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia, Leuk. Res, vol.33, pp.407-417, 2009. ,
In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia, Leuk. Res, vol.34, pp.24-31, 2010. ,
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9, The next decade, vol.48, pp.222-272, 2013. ,
Biological and pathobiological functions of gelatinase dimers and complexes, Connect. Tissue Res, vol.49, pp.180-184, 2008. ,
Human neutrophil gelatinase: A marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay, Eur. J. Haematol, vol.49, pp.180-191, 1992. ,
Production of matrix metalloproteinase-9 in early stage B-CLL: Suppression by interferons, Leukemia, vol.16, pp.791-798, 2002. ,
Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease, BMC Cancer, vol.9, p.390, 2009. ,
Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells, J. Cell Physiol, vol.215, pp.526-537, 2008. ,
Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: Comparison with normal bone marrow cells, Br. J. Haematol, vol.105, pp.402-411, 1999. ,
Granules of the human neutrophilic polymorphonuclear leukocyte, vol.89, pp.3503-3521, 1997. ,
Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures, Br. J. Haematol, vol.115, pp.595-604, 2001. ,
Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9, J. Biol. Chem, vol.273, pp.20677-20684, 1998. ,
Human T lymphocytes synthesize the 92 kDa type IV collagenase (gelatinase B), J. Cell Physiol, vol.157, pp.644-649, 1993. ,
Production and regulation of gelatinase B by human t-cells, Biochim. Biophys. Acta, vol.1176, pp.265-268, 1993. ,
Transcription factor NF-?b inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies, Curr. Mol. Pharmacol, vol.3, pp.98-122, 2010. ,
Molecular and cellular mechanisms of CLL: Novel therapeutic approaches, Nat. Rev. Clin. Oncol, vol.6, pp.405-418, 2009. ,
The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia, Br. J. Haematol, vol.125, pp.128-140, 2004. ,
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia, Eur. J. Haematol, vol.70, pp.373-378, 2003. ,
Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia, Hematology, vol.12, pp.319-324, 2007. ,
The molecular basis of T cell acute lymphoblastic leukemia, J. Clin. Invest, vol.122, pp.3398-3406, 2012. ,
MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (all) ,
, Leuk. Res, vol.25, pp.125-131, 2001.
Matrix metalloproteinase-9 and vascular endothelial growth factor: A possible link in adult T-cell leukaemia cell invasion, Br. J. Haematol, vol.116, pp.94-102, 2002. ,
Marrow matrix metalloproteinases (mmps) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia, Br. J. Haematol, vol.117, pp.835-841, 2002. ,
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia, Leuk. Lymphoma, vol.46, pp.885-891, 2005. ,
Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia, Pol. Merkur. Lekarski, vol.29, pp.14-18, 2010. ,
Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells, FASEB J, vol.25, pp.2831-2842, 2011. ,
Inactivation of interleukin-6 in vitro by monoblastic U937 cell plasma membranes involves both protease and peptidyl-transferase activities, Eur. J. Biochem, vol.215, pp.825-831, 1993. ,
A multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia, Leukemia, vol.24, pp.1105-1112, 2010. ,
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia, Leukemia, vol.25, pp.7-22, 2011. ,
Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms, Adv. Exp. Med. Biol, vol.779, pp.179-196, 2013. ,
Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes, Clin. Cancer Res, vol.5, pp.1115-1124, 1999. ,
BCR-ABL-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in matrigel implants, Leukemia, vol.16, pp.1160-1166, 2002. ,
Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray, Int. J. Oncol, vol.23, pp.681-691, 2003. ,
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis, Oncogene, vol.27, pp.6110-6119, 2008. ,
Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia, Leuk. Lymphoma, vol.49, pp.984-988, 2008. ,
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission, Acta Haematol, vol.127, pp.1-6, 2012. ,
Acute leukaemia: Making sense of a complex blood cancer, Br. J. Nurs, vol.21, pp.78-83, 2012. ,
Targeting the fms-like tyrosine kinase 3 in acute myeloid leukemia, Leukemia, vol.26, pp.2176-2185, 2012. ,
Mechanistic insights into the antileukemic activity of hyperforin, Curr. Cancer Drug Targets, vol.13, pp.1-10, 2013. ,
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: A possible relation to disease invasion, Hematology, vol.8, pp.385-391, 2003. ,
Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia, Leuk. Lymphoma, vol.54, pp.1614-1625, 2013. ,
Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases, Expert Opin. Ther. Targets, vol.8, pp.473-489, 2004. ,
, Immunity, inflammation, and cancer. Cell, vol.140, pp.883-899, 2010.
The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages, Crit. Rev. Oncol. Hematol, vol.66, pp.1-9, 2008. ,
Inflammation and cancer: How hot is the link?, Biochem. Pharmacol, vol.72, pp.1605-1621, 2006. ,
A novel role of metalloproteinase in cancer-mediated immunosuppression, Cancer Res, vol.61, pp.237-242, 2001. ,
Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis, J. Exp. Med, vol.203, pp.1007-1019, 2006. ,
Cell surface association of matrix metalloproteinase-9 (gelatinase B), Cancer Metastasis Rev, vol.22, pp.153-166, 2003. ,
The hemopexin and o-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors, J. Biol. Chem, vol.281, pp.18626-18637, 2006. ,
New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression, Biochim. Biophys. Acta, vol.1825, pp.29-36, 2012. ,
Evidence for a macromolecular complex in poor prognosis cll that contains CD38, CD49d, CD44 and MMP-9, Br. J. Haematol, vol.154, pp.216-222, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00640630
Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of ifn-alpha dendritic cells, J. Immunol, vol.176, pp.6022-6033, 2006. ,
Intracellular and cell surface localization of a complex between ?m?2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils, J. Immunol, vol.172, pp.7060-7068, 2004. ,
Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain, Cancer Cell, vol.17, pp.160-172, 2010. ,
A receptor for the lipocalin placental protein 14 on human monocytes, FEBS Lett, vol.436, pp.455-460, 1998. ,
A novel alternative spliced variant of neutrophil gelatinase-associated lipocalin receptor in oesophageal carcinoma cells, Biochem. J, vol.403, pp.297-303, 2007. ,
The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake, FEBS Lett, vol.579, pp.773-777, 2005. ,
Neutrophil gelatinase-associated lipocalin: New paths for an old shuttle. Cancer Ther, vol.5, pp.463-470, 2007. ,
Neutrophil gelatinase-associated lipocalin as a survival factor, Biochem. J, vol.391, pp.441-448, 2005. ,
Ngal decreases e-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells, vol.89, pp.531-548, 2009. ,
Ngal knockdown by sirna in human cholangiocarcinoma cells suppressed invasion by reducing ngal/mmp-9 complex formation, Clin. Exp. Metastasis, vol.27, pp.295-305, 2010. ,
The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients, Clin. Cancer Res, vol.11, pp.5390-5395, 2005. ,
Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/AKT signaling, Int. J. Oncol, vol.38, pp.325-333, 2011. ,
Neutrophil gelatinase-associated lipocalin: A novel suppressor of invasion and angiogenesis in pancreatic cancer, Cancer Res, vol.68, pp.6100-6108, 2008. ,
Neutrophil gelatinase-associated lipocalin induces the expression of heme oxygenase-1 and superoxide dismutase 1, 2. Cell Stress Chaperones, vol.15, pp.395-403, 2010. ,
Effects of ectopic expression of NGAL on doxorubicin sensitivity, Oncotarget, vol.3, pp.1236-1245, 2012. ,
Neutrophil gelatinase-associated lipocalin regulates intracellular accumulation of Rh123 in cancer cells, Genes Cells, vol.17, pp.205-217, 2012. ,
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer, Am. J. Transl. Res, vol.5, pp.481-496, 2013. ,
Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer, Eur. J. Cancer, vol.43, pp.1869-1876, 2007. ,
Up-regulation of neutrophil gelatinase-associated lipocalin in oral squamous cell carcinoma: Relation to cell differentiation, Oncol. Rep, vol.26, pp.1415-1421, 2011. ,
NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells, J. Clin. Endocrinol. Metab, vol.98, pp.228-235, 2013. ,
The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases, Eur. J. Biochem, vol.268, pp.1918-1928, 2001. ,
The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL, J. Biol. Chem, vol.276, pp.37258-37265, 2001. ,
Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells, J. Int. Cancer, vol.118, pp.2490-2497, 2006. ,
Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide, J. Biol. Chem, vol.277, pp.16022-16027, 2002. ,
Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3, Biochemistry, vol.47, pp.2689-2699, 2008. ,
Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells, Blood, vol.90, pp.1649-1655, 1997. ,
Matrix metalloproteinases in multiple myeloma, Leuk. Lymphoma, vol.37, pp.273-281, 2000. ,
Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma, Cancer, vol.100, pp.356-365, 2004. ,
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: Evidence for a role of hepatocyte growth factor, Leukemia, vol.18, pp.976-982, 2004. ,
Matrix metalloproteinases and their tissue inhibitors-expression, role and regulation in human malignant non-Hodgkin's lymphomas, Leuk. Lymphoma, vol.39, pp.485-493, 2000. ,
Molecular cloning and characterization of a novel human gene containing 4 ankyrin repeat domains, Cell Mol. Biol. Lett, vol.10, pp.185-193, 2005. ,
Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages, Eur. Heart J, vol.32, pp.2841-2850, 2011. ,
Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression, Blood, vol.108, pp.1441-1450, 2006. ,
CD44 in hematological neoplasias, Ann. hematol, vol.90, pp.493-508, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00610424
Emerging roles of proteases in tumour suppression, Nat. Rev. Cancer, vol.7, pp.800-808, 2007. ,
Progress in matrix metalloproteinase research, Mol. Asp. Med, vol.29, pp.290-308, 2008. ,
Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion, J. Biol. Chem, vol.279, pp.29589-29597, 2004. ,
The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein, J. Neurosci, vol.28, pp.11571-11582, 2008. ,
Role of matrix metalloproteinase-9 dimers in cell migration: Design of inhibitory peptides, J. Biol. Chem, vol.285, pp.35944-35956, 2010. ,
A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds ?4?1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells, J. Biol. Chem, vol.287, pp.27601-27613, 2012. ,